Company intelligence / Profile preview

Swixx BioPharma

Ownership: Private
Employees: ~1600
Development stage: Commercial

Overview

Swixx BioPharma is a specialized distributor and commercialization partner for pharmaceutical companies in Central & Eastern Europe, CIS/Eurasia, MENA, and Latin America. The company achieved over €900 million in sales in 2023 and was recognized by the Financial Times as one of Europe's fastest-growing companies with a 70.6% CAGR in 2024.

Therapeutic areas: OncologyInfectious DiseasesRare DiseasesOther
Industry: Consulting

Partnerships

AlbireoAmgenBMSKyowa KirinOtsukaSeagenJazz Pharmaceuticals

Beyond the preview

Go deeper on Swixx BioPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Swixx BioPharma.

Explore the full profile